COVID-19 vaccine induced interstitial lung disease
Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 28(2022), 1 vom: 01. Jan., Seite 95-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshifuji, Ayumi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse events |
|---|
| Anmerkungen: |
Date Completed 19.11.2021 Date Revised 19.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiac.2021.09.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331216167 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331216167 | ||
| 003 | DE-627 | ||
| 005 | 20231225212956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiac.2021.09.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331216167 | ||
| 035 | |a (NLM)34580010 | ||
| 035 | |a (PII)S1341-321X(21)00259-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshifuji, Ayumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccine induced interstitial lung disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.11.2021 | ||
| 500 | |a Date Revised 19.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Drug-induced interstitial lung disease | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Ishioka, Kota |e verfasserin |4 aut | |
| 700 | 1 | |a Masuzawa, Yuya |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Shuntaro |e verfasserin |4 aut | |
| 700 | 1 | |a Murata, Saori |e verfasserin |4 aut | |
| 700 | 1 | |a Uwamino, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujino, Motoko |e verfasserin |4 aut | |
| 700 | 1 | |a Miyahara, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Ryuzaki, Munekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshino, Haruhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sekine, Kazuhiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 28(2022), 1 vom: 01. Jan., Seite 95-98 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:95-98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiac.2021.09.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 1 |b 01 |c 01 |h 95-98 | ||